Verteporfin

Overview

Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

Indication

For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors.

Associated Conditions

Subfoveal Choroidal Neovascularization (CNV)

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer	2024/04/24	NCT06381154	Phase 2	Recruiting	Mayo Clinic
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction	2024/03/12	NCT06306638	Phase 1	Recruiting	Roswell Park Cancer Institute
Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy	2022/10/21	NCT05589974	N/A	Recruiting	Helse Stavanger HF
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma	2020/10/19	NCT04590664	Phase 1	Recruiting	Emory University
Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy	2019/08/30	NCT04075136	Phase 4	Withdrawn	Wake Forest University Health Sciences
Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen	2018/03/08	NCT03459144	Not Applicable	Completed	Sun Yat-sen University
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System	2017/03/01	NCT03067051	Phase 1	Recruiting	SpectraCure AB
Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study	2017/01/26	NCT03033225	Phase 2	Completed	Mayo Clinic
An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer	2016/10/20	NCT02939274	Phase 2	UNKNOWN	Rogers Sciences Inc.
Treatment of Primary Breast Cancer Using PDT	2016/08/18	NCT02872064	Not Applicable	Completed	University College, London

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Visudyne	Bausch Health US LLC	0187-5600	INTRAVENOUS	15 mg in 1 1	7/21/2021
Visudyne	QLT Ophthalmics, Inc.	50236-001	INTRAVENOUS	15 mg in 1 1	1/11/2010
Visudyne	Bausch & Lomb Incorporated	24208-560	INTRAVENOUS	15 mg in 1 1	2/24/2023

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
Visudyne	CHEPLAPHARM Arzneimittel GmbH,Ziegelhof 24,17489 Greifswald,Germany	Authorised	7/27/2000

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
VISUDYNE FOR INJECTION 15 mg/vial	Alcami Carolinas Corporation, Nippon Fine Chemical Co. Ltd (DP intermediate (Verteporfin Presome) manufacturer)	SIN11608P	INJECTION	15 mg/vial	8/3/2001

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
VISUDYNE POWDER FOR INJECTION 15MG	N/A	ZUELLIG PHARMA LIMITED	N/A	N/A	6/18/2001

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access